Cargando…

Low-intensity ultrasound enhances the anticancer activity of cetuximab in human head and neck cancer cells

The potential clinical use of ultrasound in inducing cell apoptosis and enhancing the effects of anticancer drugs in the treatment of cancers has previously been investigated. In this study, the combined effects of low-intensity ultrasound (LIU) and cetuximab, an anti-epidermal growth factor recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	MASUI, TAKASHI, OTA, ICHIRO, KANNO, MASATOSHI, YANE, KATSUNARI, HOSOI, HIROSHI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524017/ https://www.ncbi.nlm.nih.gov/pubmed/23251234 http://dx.doi.org/10.3892/etm.2012.739

Ejemplares similares

Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells
por: OTA, ICHIRO, et al.
Publicado: (2013)

Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells
por: Ohnishi, Ken, et al.
Publicado: (2002)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
por: Maahs, Lucas, et al.
Publicado: (2022)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
por: Dequanter, Didier, et al.
Publicado: (2010)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
por: Gustafsson, H., et al.
Publicado: (2017)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
por: Krishnamurthy, Sapna, et al.
Publicado: (2022)

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines
por: Gomes, Izabela N. F., et al.
Publicado: (2022)

Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol
por: Habl, Gregor, et al.
Publicado: (2010)

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
por: Nowsheen, Somaira, et al.
Publicado: (2011)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Two Cases of Pneumatosis Intestinalis during Cetuximab Therapy for Advanced Head and Neck Cancer
por: Miller, James A., et al.
Publicado: (2015)

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
por: Elghouche, Alhasan, et al.
Publicado: (2016)

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
por: Magnes, Teresa, et al.
Publicado: (2017)

Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer
por: Bouhaddou, Mehdi, et al.
Publicado: (2021)

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
por: Iida, Mari, et al.
Publicado: (2022)

Recapitulating the Pharmacological Interactions of Cetuximab with Sunitinib and Cisplatin in Head and Neck Carcinoma Cells in vitro
por: Dib, Maria, et al.
Publicado: (2022)

Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment
por: Liu, Ying, et al.
Publicado: (2021)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
por: Schmitz, Sandra, et al.
Publicado: (2015)

Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer
por: Vesci, Loredana, et al.
Publicado: (2015)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer
por: Schmitz, Sandra, et al.
Publicado: (2015)

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
por: Li, Jing, et al.
Publicado: (2015)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qom6b7v29ln52sa55catm6a7f8